Merck (MRK) Change in Accured Expenses (2009)

Merck (MRK) posted quarterly Change in Accured Expenses of $448.0 million for Q4 2009, up 667.09% sequentially from -$79.0 million in Q3 2009.

Merck (MRK) Change in Accured Expenses (2009) Analysis & Trends

Merck has disclosed Change in Accured Expenses across 1 years of filings, most recently posting $448.0 million for Q4 2009.

In Q4 2009, Change in Accured Expenses changed N/A year-over-year to $448.0 million; the TTM figure through Dec 2009 stood at -$910.0 million (changed N/A YoY), while the FY2025 annual figure was -$1.8 billion, down 3657.14% from the prior year.
Change in Accured Expenses grew to $448.0 million in Q4 2009, from -$79.0 million in the prior quarter.
Over the last five years, Change in Accured Expenses for MRK reached as high as $448.0 million in Q4 2009 and fell as low as -$79.0 million in Q3 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Accured Expenses (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	-
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	-629.00 Mn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-1.59 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	-
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-75.00 Mn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	-702.00 Mn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn	-243.20 Mn

Download Data